BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease
To further enhance preparedness against health security threats, BARDA is extending a partnership with Mapp Biopharmaceutical, Inc. to advance the development of MBP091, a single monoclonal antibody therapeutic to treat Marburg virus disease (MVD). If successful, MBP091 would become the first therapeutic licensed to combat Marburg virus (MARV), which is in the same viral family (filoviruses) as Sudan and Zaire ebolaviruses.